Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Cancer cell - 1 Jun 2002

Kelly Louise M, Yu Jin-Chen, Boulton Christina L, Apatira Mutiah, Li Jason, Sullivan Carol M, Williams Ifor, Amaral Sonia M, Curley David P, Duclos Nicole, Neuberg Donna, Scarborough Robert M, Pandey Anjali, Hollenbach Stanley, Abe Keith, Lokker Nathalie A, Gilliland D Gary, Giese Neill A

Abstract excerpt

Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the juxtamembrane domain of the FLT3 receptor, suggesting that it may be a target for kinase inhibitor therapy. For this purpose we have developed CT53518, a potent antagonist that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Transplantation
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-3

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Quinazolines

Share to Receptors, Platelet-Derived Growth Factor

Share to Tandem Repeat Sequences

Source

Identifiers

PMID: 12124172
DOI: 10.1016/s1535-6108(02)00070-3

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-12124172-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).PMID 12124172Read ↗

Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.Semantic proximity Read ↗

The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.Semantic proximity Read ↗

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.Semantic proximity Read ↗

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.Semantic proximity Read ↗

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentSemantic proximity Read ↗

FLT3 mutations: biology and treatment.Semantic proximity Read ↗

TIP-20, a novel feline McDonough sarcoma-like tyrosine kinase 3 inhibitor with potent antileukemia activity.Semantic proximity Read ↗

Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.Semantic proximity Read ↗

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.Semantic proximity Read ↗

FLT3 Inhibition in Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.